Elevation Oncology Inc (NASDAQ:ELEV) shares, rose in value, with the stock price down by -0.69% to the previous day’s close as strong demand from buyers drove the stock to $3.62.
Actively observing the price movement in the last trading, the stock closed the session at $3.64. Referring to stock’s 52-week performance, its high was $5.89, and the low was $0.36. On the whole, ELEV has fluctuated by -27.74% over the past month.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ELEV’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ELEV currently trading nearly -20.15% and -14.14% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.31, while the 7-day volatility ratio is showing 10.79% which for the 30-day chart, stands at 9.51%. Furthermore, Elevation Oncology Inc (ELEV)’s beta value is 1.52, and its average true range (ATR) is 0.41.
A comparison of Elevation Oncology Inc (ELEV) with its peers suggests the former has fared considerably weaker in the market. ELEV showed an intraday change of -0.69% in last session, and over the past year, it grew by 19.47%%.
Data on historical trading for Elevation Oncology Inc (NASDAQ:ELEV) indicates that the trading volumes over the past 3 months, they’ve averaged 1.19 million. According to company’s latest data on outstanding shares, there are 42.42 million shares outstanding.
Nearly 21.92% of Elevation Oncology Inc’s shares belong to company insiders and institutional investors own 66.24% of the company’s shares. The stock has risen by 574.12% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ELEV stock heading into the next quarter.
